Ascenta Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Ascenta Therapeutics sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Ascenta Therapeutics: 10 sponsored US clinical trials, none currently recruiting.
Ascenta Therapeutics sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Follicular Lymphoma, with 2 trials.
Top-decile sponsor footprint
Ascenta Therapeutics ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
10 total, page 1 of 1
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
NCT01265199
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
NCT00571675
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
NCT00544960
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
NCT00561197
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
NCT00397293
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
NCT00440388
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
NCT00286793
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
NCT00286780
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
NCT00286806
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
NCT00275431
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
Therapeutic Areas
How the Ascenta Therapeutics early-phase archive is shaped
10 indexed studies, none listed as recruiting (0% open); 8 completed (80%).
Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Follicular Lymphoma (2 trials), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Ascenta Therapeutics: archived-pipeline peers nationwide
Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Ascenta Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 archived trials
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Ascenta Therapeutics page
10 registered trials is a research-attention snapshot, not an endorsement of Ascenta Therapeutics or any single study.
- None of Ascenta Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Follicular Lymphoma is the condition Ascenta Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Follicular Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ascenta Therapeutics pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.